Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Epilepsia ; 56(9): e114-20, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26122718

ABSTRACT

Autosomal dominant mutations in the sodium-gated potassium channel subunit gene KCNT1 have been associated with two distinct seizure syndromes, nocturnal frontal lobe epilepsy (NFLE) and malignant migrating focal seizures of infancy (MMFSI). To further explore the phenotypic spectrum associated with KCNT1, we examined individuals affected with focal epilepsy or an epileptic encephalopathy for mutations in the gene. We identified KCNT1 mutations in 12 previously unreported patients with focal epilepsy, multifocal epilepsy, cardiac arrhythmia, and in a family with sudden unexpected death in epilepsy (SUDEP), in addition to patients with NFLE and MMFSI. In contrast to the 100% penetrance so far reported for KCNT1 mutations, we observed incomplete penetrance. It is notable that we report that the one KCNT1 mutation, p.Arg398Gln, can lead to either of the two distinct phenotypes, ADNFLE or MMFSI, even within the same family. This indicates that genotype-phenotype relationships for KCNT1 mutations are not straightforward. We demonstrate that KCNT1 mutations are highly pleiotropic and are associated with phenotypes other than ADNFLE and MMFSI. KCNT1 mutations are now associated with Ohtahara syndrome, MMFSI, and nocturnal focal epilepsy. They may also be associated with multifocal epilepsy and cardiac disturbances.


Subject(s)
Epilepsies, Partial/genetics , Mutation/genetics , Nerve Tissue Proteins/genetics , Potassium Channels/genetics , Adolescent , Age of Onset , Child , Child, Preschool , Female , Humans , Infant , Male , Potassium Channels, Sodium-Activated , Sudden Infant Death/genetics
2.
Epilepsia ; 54(5): e86-9, 2013 May.
Article in English | MEDLINE | ID: mdl-23566103

ABSTRACT

Heterozygous mutations in PRRT2 have recently been identified as the major cause of autosomal dominant benign familial infantile epilepsy (BFIE), infantile convulsions with choreoathetosis syndrome (ICCA), and paroxysmal kinesigenic dyskinesia (PKD). Homozygous mutations in PRRT2 have also been reported in two families with intellectual disability (ID) and seizures. Heterozygous mutations in the genes KCNQ2 and SCN2A cause the two other autosomal dominant seizure disorders of infancy: benign familial neonatal epilepsy and benign familial neonatal-infantile epilepsy. Mutations in KCNQ2 and SCN2A also contribute to severe infantile epileptic encephalopathies (IEEs) in which seizures and intellectual disability co-occur. We therefore hypothesized that PRRT2 mutations may also underlie cases of IEE. We examined PRRT2 for heterozygous, compound heterozygous or homozygous mutations to determine their frequency in causing epileptic encephalopathies (EEs). Two hundred twenty patients with EEs with onset by 2 years were phenotyped. An assay for the common PRRT2 c.649-650insC mutation and high resolution-melt analysis for mutations in the remaining exons of PRRT2 were performed. Neither the common mutation nor any other pathogenic variants in PRRT2 were detected in the 220 patients. Our findings suggest that mutations in PRRT2 are not a common cause of IEEs.


Subject(s)
Genetic Predisposition to Disease/genetics , Membrane Proteins/genetics , Mutation/genetics , Nerve Tissue Proteins/genetics , Spasms, Infantile/genetics , Age Factors , Cohort Studies , DNA Mutational Analysis , Female , Gene Frequency , Humans , Infant , Male , Phenotype
3.
Ann Neurol ; 70(6): 974-85, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22190369

ABSTRACT

OBJECTIVE: Rare copy number variants (CNVs)--deletions and duplications--have recently been established as important risk factors for both generalized and focal epilepsies. A systematic assessment of the role of CNVs in epileptic encephalopathies, the most devastating and often etiologically obscure group of epilepsies, has not been performed. METHODS: We evaluated 315 patients with epileptic encephalopathies characterized by epilepsy and progressive cognitive impairment for rare CNVs using a high-density, exon-focused, whole-genome oligonucleotide array. RESULTS: We found that 25 of 315 (7.9%) of our patients carried rare CNVs that may contribute to their phenotype, with at least one-half being clearly or likely pathogenic. We identified 2 patients with overlapping deletions at 7q21 and 2 patients with identical duplications of 16p11.2. In our cohort, large deletions were enriched in affected individuals compared to controls, and 4 patients harbored 2 rare CNVs. We screened 2 novel candidate genes found within the rare CNVs in our cohort but found no mutations in our patients with epileptic encephalopathies. We highlight several additional novel candidate genes located in CNV regions. INTERPRETATION: Our data highlight the significance of rare CNVs in the epileptic encephalopathies, and we suggest that CNV analysis should be considered in the genetic evaluation of these patients. Our findings also highlight novel candidate genes for further study.


Subject(s)
Cognition Disorders/genetics , DNA Copy Number Variations/genetics , Epilepsy/genetics , Genetic Predisposition to Disease , Calcium Channels/genetics , Chromosomes, Human, Pair 7/genetics , Cognition Disorders/complications , Epilepsy/complications , Exons/genetics , Female , Gene Dosage , Gene Expression Profiling , Humans , Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 , Male , Oligonucleotide Array Sequence Analysis/methods , Protein Serine-Threonine Kinases/genetics
4.
Brain ; 134(Pt 10): 2982-3010, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21719429

ABSTRACT

Dravet syndrome is an epilepsy syndrome of infantile onset, frequently caused by SCN1A mutations or deletions. Its prevalence, long-term evolution in adults and neuropathology are not well known. We identified a series of 22 adult patients, including three adult post-mortem cases with Dravet syndrome. For all patients, we reviewed the clinical history, seizure types and frequency, antiepileptic drugs, cognitive, social and functional outcome and results of investigations. A systematic neuropathology study was performed, with post-mortem material from three adult cases with Dravet syndrome, in comparison with controls and a range of relevant paediatric tissue. Twenty-two adults with Dravet syndrome, 10 female, were included, median age 39 years (range 20-66). SCN1A structural variation was found in 60% of the adult Dravet patients tested, including one post-mortem case with DNA extracted from brain tissue. Novel mutations were described for 11 adult patients; one patient had three SCN1A mutations. Features of Dravet syndrome in adulthood include multiple seizure types despite polytherapy, and age-dependent evolution in seizure semiology and electroencephalographic pattern. Fever sensitivity persisted through adulthood in 11 cases. Neurological decline occurred in adulthood with cognitive and motor deterioration. Dysphagia may develop in or after the fourth decade of life, leading to significant morbidity, or death. The correct diagnosis at an older age made an impact at several levels. Treatment changes improved seizure control even after years of drug resistance in all three cases with sufficient follow-up after drug changes were instituted; better control led to significant improvement in cognitive performance and quality of life in adulthood in two cases. There was no histopathological hallmark feature of Dravet syndrome in this series. Strikingly, there was remarkable preservation of neurons and interneurons in the neocortex and hippocampi of Dravet adult post-mortem cases. Our study provides evidence that Dravet syndrome is at least in part an epileptic encephalopathy.


Subject(s)
Brain/pathology , Cognition Disorders/pathology , Epilepsies, Myoclonic/pathology , Nerve Tissue Proteins/genetics , Sodium Channels/genetics , Adult , Aged , Brain/physiopathology , Cognition Disorders/genetics , Cognition Disorders/physiopathology , Disease Progression , Epilepsies, Myoclonic/genetics , Epilepsies, Myoclonic/physiopathology , Female , Humans , Male , Middle Aged , Mutation , NAV1.1 Voltage-Gated Sodium Channel , Syndrome
5.
Twin Res Hum Genet ; 13(2): 168-78, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20397747

ABSTRACT

Rett syndrome (RTT) is a severe neurodevelopmental disorder affecting females almost exclusively and is characterized by a wide spectrum of clinical manifestations. Mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene have been found in up to 95% of classical RTT cases and a lesser proportion of atypical cases. Recently, mutations in another X-linked gene, CDKL5 (cyclin-dependent kinase-like 5) have been found to cause atypical RTT, in particular the early onset seizure (Hanefeld variant) and one female with autism. In this study we screened several cohorts of children for CDKL5 mutations, totaling 316 patients, including individuals with a clinical diagnosis of RTT but who were negative for MECP2 mutations (n=102), males with X-linked mental retardation (n=9), patients with West syndrome (n=52), patients with autism (n=59), patients with epileptic encephalopathy (n=33), patients with Aicardi syndrome (n=7) and other patients with intellectual disability with or without seizures (n=54). In all, seven polymorphic variations and four de novo mutations (c.586C>T [p.S196L]; c.58G>C [p.G20R]; c.2504delC [p.P835fs]; deletion of exons 1-3) were identified, and in all instances of the latter the clinical phenotype was that of an epileptic encephalopathy. These results suggest that pathogenic CDKL5 mutations are unlikely to be identified in the absence of severe early-onset seizures and highlight the importance of screening for large intragenic and whole gene deletions.


Subject(s)
Cognition Disorders/genetics , Cyclin-Dependent Kinase 5/genetics , Mutation , Rett Syndrome/diagnosis , Rett Syndrome/genetics , Seizures/genetics , Amino Acid Sequence , Cognition Disorders/diagnosis , Cognition Disorders/enzymology , Cohort Studies , Cyclin-Dependent Kinase 5/metabolism , Female , Genetic Testing , Humans , Male , Molecular Sequence Data , Rett Syndrome/enzymology , Seizures/diagnosis , Seizures/enzymology
6.
Nat Genet ; 45(9): 1073-6, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23933818

ABSTRACT

Epilepsy-aphasia syndromes (EAS) are a group of rare, severe epileptic encephalopathies of unknown etiology with a characteristic electroencephalogram (EEG) pattern and developmental regression particularly affecting language. Rare pathogenic deletions that include GRIN2A have been implicated in neurodevelopmental disorders. We sought to delineate the pathogenic role of GRIN2A in 519 probands with epileptic encephalopathies with diverse epilepsy syndromes. We identified four probands with GRIN2A variants that segregated with the disorder in their families. Notably, all four families presented with EAS, accounting for 9% of epilepsy-aphasia cases. We did not detect pathogenic variants in GRIN2A in other epileptic encephalopathies (n = 475) nor in probands with benign childhood epilepsy with centrotemporal spikes (n = 81). We report the first monogenic cause, to our knowledge, for EAS. GRIN2A mutations are restricted to this group of cases, which has important ramifications for diagnostic testing and treatment and provides new insights into the pathogenesis of this debilitating group of conditions.


Subject(s)
Landau-Kleffner Syndrome/genetics , Mutation , Receptors, N-Methyl-D-Aspartate/genetics , Electroencephalography , Female , Humans , Landau-Kleffner Syndrome/diagnosis , Male , Pedigree , Phenotype
7.
Nat Genet ; 45(7): 825-30, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23708187

ABSTRACT

Epileptic encephalopathies are a devastating group of epilepsies with poor prognosis, of which the majority are of unknown etiology. We perform targeted massively parallel resequencing of 19 known and 46 candidate genes for epileptic encephalopathy in 500 affected individuals (cases) to identify new genes involved and to investigate the phenotypic spectrum associated with mutations in known genes. Overall, we identified pathogenic mutations in 10% of our cohort. Six of the 46 candidate genes had 1 or more pathogenic variants, collectively accounting for 3% of our cohort. We show that de novo CHD2 and SYNGAP1 mutations are new causes of epileptic encephalopathies, accounting for 1.2% and 1% of cases, respectively. We also expand the phenotypic spectra explained by SCN1A, SCN2A and SCN8A mutations. To our knowledge, this is the largest cohort of cases with epileptic encephalopathies to undergo targeted resequencing. Implementation of this rapid and efficient method will change diagnosis and understanding of the molecular etiologies of these disorders.


Subject(s)
DNA Mutational Analysis/methods , DNA-Binding Proteins/genetics , Epilepsy/genetics , Mutation , ras GTPase-Activating Proteins/genetics , Adolescent , Adult , Child , Child, Preschool , Cohort Studies , Epilepsy/diagnosis , Epilepsy/epidemiology , Female , Genetic Predisposition to Disease/genetics , Humans , Male , Mutation/physiology , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL